These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16946199)

  • 1. Comparing antipsychotic efficacy.
    Tandon R
    Am J Psychiatry; 2006 Sep; 163(9):1645. PubMed ID: 16946199
    [No Abstract]   [Full Text] [Related]  

  • 2. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.
    Heres S; Davis J; Maino K; Jetzinger E; Kissling W; Leucht S
    Am J Psychiatry; 2006 Feb; 163(2):185-94. PubMed ID: 16449469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of schizophrenia drugs often favors firm funding study.
    Vendantam S
    Washington Post; 2006 Apr; ():A1, A6. PubMed ID: 16856276
    [No Abstract]   [Full Text] [Related]  

  • 4. [Industry-promoted research and the significance principle].
    Klin Monbl Augenheilkd; 2001 May; 218(5):A90-1. PubMed ID: 11417352
    [No Abstract]   [Full Text] [Related]  

  • 5. Methodological concerns in a trial of ziprasidone and olanzapine.
    Ross DE
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994735
    [No Abstract]   [Full Text] [Related]  

  • 6. Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses.
    Tandon R; Nasrallah HA
    Arch Gen Psychiatry; 2006 Aug; 63(8):935-7; author reply 937-9. PubMed ID: 16894070
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmaceutical company-sponsored drug trials: what are we to believe?
    Shekelle P
    J Clin Epidemiol; 2010 Feb; 63(2):126-7. PubMed ID: 19836207
    [No Abstract]   [Full Text] [Related]  

  • 8. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.
    Montgomery JH; Byerly M; Carmody T; Li B; Miller DR; Varghese F; Holland R
    Control Clin Trials; 2004 Dec; 25(6):598-612. PubMed ID: 15588746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ACCOMPLISH and the risks with company sponsored clinical trials].
    Furberg C
    Lakartidningen; 2009 Feb 11-17; 106(7):450. PubMed ID: 19350775
    [No Abstract]   [Full Text] [Related]  

  • 10. The costs of drugs for schizophrenia.
    Freedman R; Carpenter WT; Davis JM; Goldman HH; Tamminga CA; Thomas M
    Am J Psychiatry; 2006 Dec; 163(12):2029-31. PubMed ID: 17151146
    [No Abstract]   [Full Text] [Related]  

  • 11. Reporting bias in industry-supported medication trials presented at the American Psychiatric Association meeting.
    Sen S; Prabhu M
    J Clin Psychopharmacol; 2012 Jun; 32(3):435. PubMed ID: 22561482
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceutical company-sponsored drug trials: the system is broken.
    Gartlehner G; Fleg A
    J Clin Epidemiol; 2010 Feb; 63(2):128-9. PubMed ID: 19880288
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
    Lieberman JA
    Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808
    [No Abstract]   [Full Text] [Related]  

  • 14. First- vs second-generation antipsychotic drugs in schizophrenia.
    Andrade C; Kharawala S
    Arch Gen Psychiatry; 2007 Aug; 64(8):978-9; author reply 979-80. PubMed ID: 17679643
    [No Abstract]   [Full Text] [Related]  

  • 15. Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Rosenheck RA
    Arch Gen Psychiatry; 2006 Oct; 63(10):1074-6. PubMed ID: 17015809
    [No Abstract]   [Full Text] [Related]  

  • 16. The CATIE study.
    Teich J
    Am J Psychiatry; 2006 Mar; 163(3):554-5; author reply 555-6. PubMed ID: 16513894
    [No Abstract]   [Full Text] [Related]  

  • 17. [Priority for atypical antipsychotics--comments on the article by Dose M. Priority for Atypicals? Current studies clarify some aspects. Psychiat Prax 2007; 34:46-49].
    Fritze J; Aldenhoff J; Bergmann F; Eckermann G; Maier W; Möller HJ; Gaebel W
    Psychiatr Prax; 2008 Mar; 35(2):94-7; author reply 97-8. PubMed ID: 17987542
    [No Abstract]   [Full Text] [Related]  

  • 18. Qualms about balms: perspectives on antidepressants.
    Greenberg RP
    J Nerv Ment Dis; 2001 May; 189(5):296-8. PubMed ID: 11379972
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of schizophrenia pharmacotherapy.
    Soumerai SB; Law MR
    Am J Psychiatry; 2007 Apr; 164(4):678; author reply 678-9. PubMed ID: 17403984
    [No Abstract]   [Full Text] [Related]  

  • 20. Issues that may determine the outcome of antipsychotic trials: industry sponsorship and extrapyramidal side effect.
    Davis JM; Chen N; Glick ID
    Neuropsychopharmacology; 2008 Apr; 33(5):971-5. PubMed ID: 17609679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.